{
    "organizations": [],
    "uuid": "2c03ff6d0233cec6122d2aafb0c137618c8ca4b6",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-strongbridge-announces-acquisition/brief-strongbridge-announces-acquisition-of-u-s-canadian-rights-to-macrilen-from-aeterna-zentaris-idUSASB0C17P",
    "ord_in_thread": 0,
    "title": "BRIEF-Strongbridge Announces Acquisition Of U.S., Canadian Rights To Macrilen From Aeterna Zentaris",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 17 (Reuters) - Strongbridge Biopharma Plc:\n* STRONGBRIDGE BIOPHARMA PLC ANNOUNCES ACQUISITION OF THE U.S. AND CANADIAN RIGHTS TO MACRILEN™ (MACIMORELIN) FROM AETERNA ZENTARIS\n* STRONGBRIDGE BIOPHARMA - ‍UNDER TERMS OF AGREEMENT, CO TO MAKE UPFRONT PAYMENT OF $24 MILLION TO AETERNA WITHIN 5 DAYS OF EFFECTIVE DATE OF AGREEMENT​\n* STRONGBRIDGE BIOPHARMA - LICENSE & ASSIGNMENT AGREEMENT ALSO PROVIDES CO WITH EXCLUSIVE LICENSE TO MANUFACTURE & COMMERCIALIZE MACRILEN IN U.S. & CANADA\n* STRONGBRIDGE BIOPHARMA PLC - STRONGBRIDGE EXPECTS TO COMMERCIALLY LAUNCH MACRILEN IN MID-YEAR 2018\n* STRONGBRIDGE BIOPHARMA PLC - ‍EXPANDS STRUCTURED FINANCING FACILITY WITH CRG TO SUPPORT ANTICIPATED COMMERCIAL LAUNCH OF MACRILEN IN MID-2018​\n* STRONGBRIDGE BIOPHARMA - AETERNA ZENTARIS WILL REMAIN RESPONSIBLE FOR A PEDIATRIC DEVELOPMENT PROGRAM TO SUPPORT REGULATORY SUBMISSION FOR MACRILEN APPROVAL\n* STRONGBRIDGE - ‍IN CONJUNCTION WITH MACRILEN DEAL, CO, CRG AMENDED EXISTING SENIOR CREDIT FACILITY TO INCREASE TOTAL POTENTIAL BORROWING TO $100 MILLION​\n* STRONGBRIDGE BIOPHARMA-CO SHARING OVERSIGHT AND PAYING FOR 70 PERCENT OF COST OF PEDIATRIC DEVELOPMENT PROGRAM OR ABOUT $4 MILLION OVER A 3-YEAR PERIOD​\n* STRONGBRIDGE - ‍UNDER AMENDED FACILITY, CO RETAINED OPTION TO BORROW ADDITIONAL $10 MILLION BASED UPON SOME CONDITIONS​\n* STRONGBRIDGE - ‍INTENDS TO USE UPFRONT PROCEEDS FROM SECOND BORROWING TO FUND ACQUISITON, COMMERCIALIZATION OF MACRILEN, CORPORATE PURPOSES​\n* STRONGBRIDGE BIOPHARMA - TERM OF LOAN UNDER CREDIT FACILITY REMAINS 6 YRS, ALTHOUGH INTEREST-ONLY PERIOD HAS BEEN EXTENDED BY 6 MONTHS TO DEC 31, 2020\n* STRONGBRIDGE BIOPHARMA- ‍AS CONDITION TO SECOND BORROWING, ISSUED WARRANTS WITH 7-YEAR TERM TO CRG TO BUY 1.2 MILLION SHARES AT EXERCISE PRICE OF $10.00PER SHARE Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-17T20:51:00.000+02:00",
    "crawled": "2018-01-18T16:23:58.028+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "strongbridge",
        "biopharma",
        "plc",
        "strongbridge",
        "biopharma",
        "plc",
        "announces",
        "acquisition",
        "canadian",
        "right",
        "macimorelin",
        "aeterna",
        "zentaris",
        "strongbridge",
        "biopharma",
        "term",
        "agreement",
        "co",
        "make",
        "upfront",
        "payment",
        "million",
        "aeterna",
        "within",
        "day",
        "effective",
        "date",
        "strongbridge",
        "biopharma",
        "license",
        "assignment",
        "agreement",
        "also",
        "provides",
        "co",
        "exclusive",
        "license",
        "manufacture",
        "commercialize",
        "macrilen",
        "canada",
        "strongbridge",
        "biopharma",
        "plc",
        "strongbridge",
        "expects",
        "commercially",
        "launch",
        "macrilen",
        "strongbridge",
        "biopharma",
        "plc",
        "structured",
        "financing",
        "facility",
        "crg",
        "support",
        "anticipated",
        "commercial",
        "launch",
        "macrilen",
        "strongbridge",
        "biopharma",
        "aeterna",
        "zentaris",
        "remain",
        "responsible",
        "pediatric",
        "development",
        "program",
        "support",
        "regulatory",
        "submission",
        "macrilen",
        "approval",
        "strongbridge",
        "conjunction",
        "macrilen",
        "deal",
        "co",
        "crg",
        "amended",
        "existing",
        "senior",
        "credit",
        "facility",
        "increase",
        "total",
        "potential",
        "borrowing",
        "strongbridge",
        "sharing",
        "oversight",
        "paying",
        "percent",
        "cost",
        "pediatric",
        "development",
        "program",
        "million",
        "strongbridge",
        "amended",
        "facility",
        "co",
        "retained",
        "option",
        "borrow",
        "additional",
        "million",
        "based",
        "upon",
        "strongbridge",
        "use",
        "upfront",
        "proceeds",
        "second",
        "borrowing",
        "fund",
        "acquisiton",
        "commercialization",
        "macrilen",
        "corporate",
        "strongbridge",
        "biopharma",
        "term",
        "loan",
        "credit",
        "facility",
        "remains",
        "yr",
        "although",
        "period",
        "extended",
        "month",
        "dec",
        "strongbridge",
        "condition",
        "second",
        "borrowing",
        "issued",
        "warrant",
        "term",
        "crg",
        "buy",
        "million",
        "share",
        "exercise",
        "price",
        "share",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}